/Companies

Alcolase

Copenhagen, DK · Founded 2021 · 9 employees on LinkedIn · 7 known investors

Find your way into Alcolase

Sign up to see every warm intro you have to Alcolase

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Alcolase team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Alcolase is a biotech company developing science-based solutions for people with alcohol intolerance, a genetic condition affecting hundreds of millions of people, particularly in East Asia. It focuses on enzyme-based products to help those who experience adverse reactions to alcohol.

Founders & leadership

Alcolase was founded in 2021 by Mikkel Precht.

MPMikkel Precht
Mikkel PrechtCEO and Co-founderFounder and CEO of Alcolase, which develops an enzyme supplement to help people with alcohol intolerance metabolize alcohol more effectively.
IC
Ib ChristensenFounder
JM
Jeppe Malthe MikkelsenFounder
ME
Mads Emil MikkelsenFounder

Investors · 7

Also in the syndicate · 1

Manigoff Investlead

Funding

SEC filings, press & company announcements

Source: company announcements and press reports — follow each round's link for the claim.

Company profile

researched Aug 2026

Alcolase is a Copenhagen-based biotechnology company developing an orally administered enzyme supplement intended for people with alcohol intolerance, in particular those carrying an ALDH2 deficiency. The product is a liposomal enzyme system: three enzymes are encapsulated inside liposomes and delivered to the stomach when the supplement is taken before drinking, where they are designed to convert ethanol into byproducts before the alcohol is absorbed into the bloodstream.

The company frames its approach as working alongside the body's own alcohol metabolism, supporting the breakdown of both ethanol and acetaldehyde in the stomach rather than after systemic absorption. Alcolase describes the product as still in development and positions it as the first enzyme supplement created specifically for alcohol intolerance.

Business model

Consumer supplement product taken before drinking alcohol; the company is at the development stage and has not disclosed commercial terms.

▸Full profile — market position, technology, go-to-market, geography

Market position

Alcolase describes its product as the world's first enzyme supplement developed for alcohol intolerance and states that no effective solution currently exists on the market for the condition.

Technology

The core technology is a liposomal delivery system that encapsulates three enzymes so they can reach the stomach intact. Once delivered, the enzymes are intended to catalyse the conversion of ethanol into harmless byproducts in the stomach, ahead of absorption into the bloodstream, and to support the breakdown of acetaldehyde as part of the body's existing alcohol metabolism pathway.

Go-to-market

Consumers affected by alcohol intolerance, specifically the estimated 540 million people worldwide who carry an ALDH2 deficiency that can make drinking alcohol painful or potentially dangerous.

Geography

Headquartered in Copenhagen, Denmark, with Singapore and South Korea identified as initial target markets.

Compiled by commissioned research from 1 cited public sources — announcements, filings, and press listed under research sources below.

Key figures

latest reported
Estimated global population with ALDH2 deficiency (addressable market)Jan 2024540,000,000 people

Company-reported or press-reported figures, each dated to when it was claimed — not independently audited.

Founder mafia

2 people who came through Alcolase went on to found or lead other companies.

In the news

▸Research sources · 1

primary sources listed

1 public sources were cited for this profile; the first-party ones are listed here.

Frequently asked questions

What does Alcolase do?
Copenhagen-based biotech developing a liposomal enzyme supplement that breaks down alcohol in the stomach for people with alcohol intolerance.
Who founded Alcolase?
Alcolase was founded by Mikkel Precht in 2021.
Who are Alcolase's investors?
Alcolase's investors include Ada Ventures, Antler, Antler Australia, Delphinus Venture Capital, Elmehøj Ventures, Selvedge Venture.
Where is Alcolase headquartered?
Alcolase is headquartered in Copenhagen, DK.